Novartis/Orion triple-combo Parkinson’s submission
This article was originally published in Pharmaceutical Approvals Monthly
Novartis and Orion Pharma submit NDA for first triple-combination Parkinson's disease therapy, the firms announce Aug. 26. The combination adds entacapone (Orion's Comtan) to the standard regimen for Parkinson's: levodopa and carbidopa. Entacapone, which is approved for patients with idiopathic Parkinson's disease who experience signs and symptoms of end-of-dose "wearing off," reduces the breakdown of levodopa, allowing it to remain therapeutically available for longer periods between doses. A triple-combination product would provide more convenient dosing, the firms sa
You may also be interested in...
Novartis/Orion's idiopathic Parkinson's disease therapy Stalevo (carbidopa, levodopa and entacapone) clears FDA June 11. The combination product adds entacapone (Novartis/Orion's Comtan) to the standard Parkinson's regimen of levodopa/carbidopa. Labeling says Stalevo can be used as a substitute for taking levodopa/carbidopa and Comtan separately. The firms have highlighted more convenient dosing as an advantage of the combo product (1Pharmaceutical Approvals Monthly Sept. 1, 2002, p. 59
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.
The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.